Category Archives: Special 301 report

Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay Millions in Costs

In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted that it had evidence to support new uses for the … Continue reading

Posted in Investor state dispute, NAFTA, Special 301 report, Uncategorized, USTR, USTR 301 report | Leave a comment

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

US continues to keep India on intellectual property priority watch list

By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of other countries.

Posted in IPR, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

On IP Protection, USTR Finds Fault With China, India … And Switzerland?

BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns about possible inadequate protection of US intellectual … Continue reading

Posted in IPR, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

US Special 301 inconsistent with WTO rules, says India

Source: Hindu BusinessLine | APRIL 25, 2016  India has said that the US Special 301 report, which tries to put pressure on countries to enhance their intellectual property rights (IPRs) legislation, violated World Trade Organization (WTO) rules.

Posted in Priority Review, Special 301 report, Uncategorized | Leave a comment

Nothing Special (301) to report

The annual IP report is expected soon By KM Gopakumar, The Hindu BusinessLine The Special 301 Report, an annual feature from the US that evaluates global intellectual property (IP) protection and enforcement in other countries, is expected to be out … Continue reading

Posted in Special 301 report, Uncategorized | Leave a comment

U.S. industry body says India agreed to not issue ‘compulsory’ drug licences

By Zeba Siddiqui, Reuters|March 9, 2016 India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers, a U.S. business advocacy group said.

Posted in Compulsory Licensing, Special 301 report, Uncategorized, USTR 301 report | Leave a comment